Literature DB >> 26604044

Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma.

Alberta Cappelli1, Alessandro Cucchetti2, Giuseppe Cabibbo3, Cristina Mosconi1, Marcello Maida3, Simona Attardo3, Irene Pettinari1, Antonio D Pinna2, Rita Golfieri1.   

Abstract

BACKGROUND & AIMS: To develop an individual prognostic calculator for patients with unresectable hepatocellular carcinoma (HCC) undergoing trans-arterial chemo-embolization (TACE).
METHODS: Data from two prospective databases, regarding 361 patients who received TACE as first-line therapy (2000-2012), were reviewed in order to refine available prognostic tools and to develop a continuous individual web-based prognostic calculator. Patients with neoplastic portal vein invasion were excluded from the analysis. The model was built following a bootstrap resampling procedure aimed at identifying prognostic predictors and by carrying out a 10-fold cross-validation for accuracy assessment by means of Harrell's c-statistic.
RESULTS: Number of tumours, serum albumin, serum total bilirubin, alpha-foetoprotein and maximum tumour size were selected as predictors of mortality following TACE with the bootstrap resampling technique. In the 10-fold cross-validation cohort, the model showed a Harrell's c-statistic of 0.649 (95% CI: 0.610-0.688), significantly higher than that of the Hepatoma Arterial-embolization Prognostic (HAP) score (0.589; 95% CI: 0.552-0.626; P = 0.001) and of the modified HAP-II score (0.611; 95% CI: 0.572-0.650; P = 0.005). Akaike's information criterion for the model was 2520; for the mHAP-II it was 2544 and for the HAP score it was 2554. A web-based calculator was developed for quick consultation at http://www.livercancer.eu/mhap3.html.
CONCLUSIONS: The proposed individual prognostic model can provide an accurate prognostic prediction for each patient with unresectable HCC following treatment with TACE without class stratification. The availability of an online calculator can help physicians in daily clinical practice.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  embolization; hepatocellular carcinoma; prognosis; survival; trans-arterial chemo-embolization

Mesh:

Substances:

Year:  2015        PMID: 26604044     DOI: 10.1111/liv.13029

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  18 in total

1.  Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads.

Authors:  Sihang Cheng; Xiang Yu; Siyun Liu; Zhengyu Jin; Huadan Xue; Zhiwei Wang; Ping Xie
Journal:  Cancer Manag Res       Date:  2021-12-24       Impact factor: 3.989

2.  Prediction of Early Treatment Response to Initial Conventional Transarterial Chemoembolization Therapy for Hepatocellular Carcinoma by Machine-Learning Model Based on Computed Tomography.

Authors:  Zhi Dong; Yingyu Lin; Fangzeng Lin; Xuyi Luo; Zhi Lin; Yinhong Zhang; Lujie Li; Zi-Ping Li; Shi-Ting Feng; Huasong Cai; Zhenpeng Peng
Journal:  J Hepatocell Carcinoma       Date:  2021-11-30

3.  Preoperative estimation of the survival of patients with unresectable hepatocellular carcinoma achieving complete response after conventional transcatheter arterial chemoembolization: assessments of clinical and LI-RADS MR features.

Authors:  Wenlong Song; Qianyu Chen; Dajing Guo; Caiming Jiang
Journal:  Radiol Med       Date:  2022-08-26       Impact factor: 6.313

Review 4.  Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Giacomo Emanuele Maria Rizzo; Giuseppe Cabibbo; Antonio Craxì
Journal:  Viruses       Date:  2022-05-07       Impact factor: 5.818

5.  Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

Authors:  Claudia Campani; Alessandro Vitale; Gabriele Dragoni; Umberto Arena; Giacomo Laffi; Umberto Cillo; Edoardo G Giannini; Francesco Tovoli; Gian Ludovico Rapaccini; Maria Di Marco; Eugenio Caturelli; Marco Zoli; Rodolfo Sacco; Giuseppe Cabibbo; Andrea Mega; Maria Guarino; Antonio Gasbarrini; Gianluca Svegliati-Baroni; Francesco Giuseppe Foschi; Elisabetta Biasini; Alberto Masotto; Gerardo Nardone; Giovanni Raimondo; Francesco Azzaroli; Gianpaolo Vidili; Maurizia Rossana Brunetto; Fabio Farinati; Franco Trevisani; Fabio Marra
Journal:  Liver Cancer       Date:  2021-03-17       Impact factor: 11.740

6.  Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma.

Authors:  Mingyu Chen; Jiasheng Cao; Jiahao Hu; Win Topatana; Shijie Li; Sarun Juengpanich; Jian Lin; Chenhao Tong; Jiliang Shen; Bin Zhang; Jennifer Wu; Christine Pocha; Masatoshi Kudo; Amedeo Amedei; Franco Trevisani; Pil Soo Sung; Victor M Zaydfudim; Tatsuo Kanda; Xiujun Cai
Journal:  Liver Cancer       Date:  2021-01-07       Impact factor: 11.740

Review 7.  The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies.

Authors:  Jens U Marquardt; Anna Saborowski; Carolin Czauderna; Arndt Vogel
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.864

8.  Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients.

Authors:  Alessandro Cucchetti; Carlo Sposito; Antonio Daniele Pinna; Davide Citterio; Matteo Cescon; Marco Bongini; Giorgio Ercolani; Christian Cotsoglou; Lorenzo Maroni; Vincenzo Mazzaferro
Journal:  World J Gastroenterol       Date:  2017-02-28       Impact factor: 5.742

9.  Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma.

Authors:  Aline Mähringer-Kunz; Arndt Weinmann; Irene Schmidtmann; Sandra Koch; Sebastian Schotten; Daniel Pinto Dos Santos; Michael Bernhard Pitton; Christoph Dueber; Peter Robert Galle; Roman Kloeckner
Journal:  BMC Cancer       Date:  2018-04-27       Impact factor: 4.430

10.  Expected outcomes and patients' selection before chemoembolization-"Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts results.

Authors:  Xavier Adhoute; Edouard Larrey; Rodolphe Anty; Patrick Chevallier; Guillaume Penaranda; Albert Tran; Jean-Pierre Bronowicki; Jean-Luc Raoul; Paul Castellani; Hervé Perrier; Olivier Bayle; Olivier Monnet; Bernard Pol; Marc Bourliere
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.